The Efficacy and Safety of Tocilizumab for Severe RP-ILD Secondary to Systemic Diseases

NCT05181397 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

68

Enrollment

OTHER

Sponsor class

Conditions

Rapid Progressive Interstitial Lung Diseases

Interventions

DRUG: Tocilizumab

Sponsor

Peking Union Medical College Hospital